Revenue Breakdown
Composition ()
No data
Revenue Streams
ADC Therapeutics SA (ADCT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product, accounting for 96.1% of total sales, equivalent to $20.03M. Other significant revenue streams include Royalties and Royalty Revenue. Understanding this composition is critical for investors evaluating how ADCT navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, ADC Therapeutics SA maintains a gross margin of 82.66%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -121.07%, while the net margin is -158.11%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ADCT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ADCT competes directly with industry leaders such as FULC and OVID. With a market capitalization of $442.63M, it holds a significant position in the sector. When comparing efficiency, ADCT's gross margin of 82.66% stands against FULC's N/A and OVID's 100.00%. Such benchmarking helps identify whether ADC Therapeutics SA is trading at a premium or discount relative to its financial performance.
